As of 1 April 2023, Integrated Shield Plans (IPs) no longer provide “As Charged” benefits to all policyholders. This is with the exception of patients with an IP and who are on cancer drug treatments as of 31 March 2023. For this group, IP insurers have committed to maintaining their current IP coverage until 30 September 2023.
For everyone else, what changes and solutions do you need to know and consider in your IP coverage? Here’s what you need to know.
What are the changes affecting policyholders with an IP?
| Outpatient Benefits |
| Before 1 April 2023 |
On and after 1 April 2023 |
| Chemotherapy |
As Charged |
Removed |
| Immunotherapy |
As Charged |
Replaced with the following:
| Outpatient Benefits |
| On and after 1 April 2023 |
| Cancer Drug Treatment (CDT) benefit/month |
Up to 5 times of MSHL* Limit |
| Cancer Drug Services (CDS) benefit/policy year |
Up to 5 times of MSHL* Limit |
*MediShield Life
Cancer Drug Treatment (CDT) benefit per month
- Only outpatient cancer drug treatments on the Cancer Drug List (CDL) will be claimable under your
...
